finerenone
Sign in to saveAlso known as BAY 94-8862
Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroid
Key facts
- Drug.image
- Finerenone.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Kerendia
- Drug.MedlinePlus
- a621038
- Drug.DailyMedID
- Finerenone
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Oral
- Drug.class
- Potassium-sparing diuretic
- Drug.ATC_prefix
- C03
- Drug.ATC_suffix
- DA05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1050477-31-0
- Drug.PubChem
- 60150535
- Drug.DrugBank
- DB16165
- Drug.ChemSpiderID
- 28669387
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 378.169191
Show 5 more facts
- chemical formula
- C₂₁H₂₂N₄O₃
- isomeric SMILES
- CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
- canonical SMILES
- CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
- physically interacts with
- Nuclear receptor subfamily 3 group C member 2
- Commons category
- Finerenone
via Wikidata · CC0
~5 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Pharmacology
- Adverse effects
- History
- Legal status
- Brand names
- Research
- References
- Further reading
Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It is taken orally (swallowed by mouth).
Common side effects include abnormally high levels of potassium in the bloodstream, abnormally low levels of sodium in the bloodstream, and abnormally low blood pressure.
Excerpted from Wikipedia’s “finerenone” article, available under the CC BY-SA 4.0 licence.
Available in 16 languages
- Español
- Français
- Deutsch
- 中文
- Русский
- Português
- Italiano
- العربية
- Bahasa Indonesia
- Greek
- Macedonian
- Odia
- Serbian
- Tiếng Việt
- Türkçe
via Wikidata sitelinks · CC0